Navigation Links
CMC Contrast Granted Orphan Drug Designation by the FDA for its Liver Specific MRI Contrast Media CMC-001
Date:11/27/2013

LUND, Sweden, November 27, 2013 /PRNewswire/ --

CMC Contrast AB, a privately owned drug development company that is developing a targeted contrast agent for Magnetic Resonance Imaging (MRI), announced today that Orphan Drug Designation has been granted by the US Food and Drug Administration (FDA) for its liver specific contrast agent CMC-001. The Orphan Drug Designation has been granted for CMC-001 for use as a targeted contrast agent for diagnostic MRI for detection and localization of focal liver lesions in patients where gadolinium-based contrast agents are contraindicated or cannot be administered.

Orphan Drug Designation is granted by the FDA Office of Orphan Drug Products to novel drugs intended to treat a rare disease or condition affecting fewer than 200,000 people in the U.S. The designation confers special incentives to the drug developer, including tax credits towards the cost of clinical trials, prescription drug user fee waivers and may entitle a period of seven years U.S market exclusivity upon FDA approval.

Magnus Corfitzen, Chairman of CMC Contrast AB "The diagnostic benefits of enhanced MRI liver imaging in detecting and localizing focal liver lesions are well established. However, a small subset of patient groups cannot undergo enhanced liver MRI procedures due to the risks of severe side effects associated with currently used gadolinium based contrast agents. For these patients, including patients with severe chronic renal insufficiency, important diagnostic information may be missed due to lack of contrast enhanced MRI. CMC-001 will allow radiologists to obtain the best possible diagnostic information in these subsets of patients, enabling clinicians to select the optimal treatment option for these patients. This is not possible today as clinicians only have access to data from an unenhanced imaging procedure on which they will base their disease management decisions for these patients"

The
'/>"/>

SOURCE CMC Contrast
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Medical Imaging Markets: Contrast Agents
2. Radiopharmaceuticals and Contrast Media: Frost & Sullivan Predicts Market Growth in Europe
3. Diagnostic Imaging Covers Communicating Contrast Agent Risk
4. Contrasting Reimbursement Environments Result in Different Prescribing Patterns for Premium-Priced Therapies in China and South Korea
5. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
6. Broad Patent Protection Granted for iBio Immunomodulator
7. BiO2 Medical Granted CE Mark for the Angel™ Catheter, the First IVC Filter with a Prophylactic Use Indication
8. QRxPharma Granted Additional US Patent on MoxDuo®
9. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
10. Unilife Granted Key U.S. Patent for Unifill Prefilled Syringe
11. Vomaris patent estate grows to six issued U.S. patents and three granted international patents with U.S. Pat. No. 8,224,439
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  The Academy ... Food and Drug Administration,s (FDA,s) draft guidance and ... products and biosimilars, to bear a nonproprietary name ... has been seeking a decision from the FDA ... diverse health care stakeholders urging the agency to ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ ... in the commercial development of the company,s supplemental ... Smart Oxygen device, being developed by ieCrowd,s subsidiary ... a patient,s changing demand for oxygen based on ... 510 (k) submission for the Smart Oxygen device ...
(Date:8/27/2015)... N.J. , Aug. 27, 2015   Women Grow , ... cannabis industry, is partnering with the Cannabis World Congress ... to produce 15 business-focused educational sessions. CWCBExpo in ... Los Angeles Convention Center in ... event on the West Coast for the marijuana industry. ...
Breaking Medicine Technology:AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 3Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 4
... subsequently,respond, have substantially more treatment costs, and ... COLORADO SPRINGS, Colo., April 03, 2007 /PRNewswire-FirstCall/,-- ... Congress on,Schizophrenia Research (ICOSR) suggest that antipsychotic ... thought, and,challenge the current schizophrenia treatment paradigm ...
... Amyloid Plaque Formation, ANNAPOLIS, Md., April 03, ... company specializing in the development,and commercialization of ... today that new data from its,recombinant butyrylcholinesterase ... 8th International Conference on,Alzheimer's and Parkinson's Diseases ...
Cached Medicine Technology:New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 2New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 3New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 4New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 6PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 2PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 3PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 4PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 5PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 6
(Date:8/29/2015)... , ... August 29, 2015 , ... ... include treating the localized area with stretching, soft tissue manipulation. Platelet rich plasma ... position have shown through research to improve treatment outcomes. This localized treatment ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... management, Decatur County Memorial Hospital recently transitioned management companies to partner with Wound ... Management for their outpatient wound center. , Transitioning wound care management providers ...
(Date:8/28/2015)... , ... August 28, 2015 , ... An article ... local pizza maker Paul LaRocco has gone through to open a pizzeria in Westchester. ... permitting process tends to take several months, but the current process, having already gone ...
(Date:8/28/2015)... ... 28, 2015 , ... As reported by Medical Daily on August 22 ... results that last for two years, the longest of any cellulite reduction system currently ... for a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director ...
(Date:8/28/2015)... ... 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, a ... carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch that ... Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected by ...
Breaking Medicine News(10 mins):Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... Digirad Corporation,(Nasdaq: DRAD ), a leading provider ... offices, hospitals and imaging centers, today,announced that it ... Program,for San Diego. The prestigious honor recognizes the ... in the,San Diego area based on percentage revenue ...
... NEW YORK, Oct. 15 Highlands Acquisition Corp.,(Amex: ... for,the Company,s initial public offering have exercised in ... public offering. As,a result, the Company sold an ... share of common stock and one warrant to ...
... SEOUL, South Korea, Oct. 15 Dong-A PharmTech Co. ... contract with,Otechestvennye Lekarstva OJSC, to market in Russia Dong-A,s ... the brand name of,Zydena. Under the terms of ... pharmaceutical firms, will pay both upfront fees and,running royalty ...
... Ended 2007, BANGOR, Maine, Oct. 15 Nyer Medical ... results for its,fiscal year ended June 30, 2007. Revenues increased ... compared to $63,596,975 as reported for,the same period ended June ... $.02 basic net earnings per common share for the year ...
... Findings could bring new treatment options for patients, ... -- Surgery patients may one day find nicotine ... prescription pad, researchers say. , Nicotine patches and ... following surgery, according to two studies presented at ...
... FORT WORTH, Texas, Oct. 15 DSS Research asked ... around PFFS sales,practices in their June Senior Trax(TM) survey. ... Medicare eligibles. Overall, 13.3% said they,had heard or read ... past two months. This figure ranged from a high ...
Cached Medicine News:Health News:Digirad Corporation Named to Deloitte Technology Fast 50 2Health News:Digirad Corporation Named to Deloitte Technology Fast 50 3Health News:Highlands Acquisition Corp. Announces Exercise of Over-Allotment Option 2Health News:Dong-A PharmTech Signs Licensing Deal With Otechestvennye to Market Zydena in Russia 2Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 2Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 3Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 4Health News:Nicotine, Chili Peppers Offer Post-Surgery Pain Relief 2Health News:Nicotine, Chili Peppers Offer Post-Surgery Pain Relief 3
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Extremely fine straight....
Curved delicate 5 mm blades....
Medicine Products: